In December 2020, the Centers for Medicare and Medicaid Services (CMS) finalized a rule around best price impact for manufacturer co-pay assistance programs affected by accumulator adjustments, that will become effective in 2023. Stay on top of these new industry standards by exploring the rule and learning how to adjust your strategies and practices with agility. Industry experts will discuss:

  • Implications of the rule for manufacturer programs and areas of intersection with other recent drug pricing rules and policy developments
  • An assessment framework for manufacturers to understand the impact of the rule specific to their program
  • Program adjustment strategies to enable manufacturers to continue delivering patient assistance in a compliant manner

Webinar Speakers

Jason Zemcik
Jason Zemcik
Senior Director, Product Manager